Stephen Dolinski
Psychiatry · Philadelphia, PANPI 1134171846
Payments from drug & device makers
Across 150 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$572
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$485
- Otsuka America Pharmaceutical, Inc.$435
- Lundbeck LLC$222
- Supernus Pharmaceuticals, Inc.$193
- Takeda Pharmaceuticals U.S.A., Inc.$160
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,06998%
- Education$762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $572 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $485 |
| Otsuka America Pharmaceutical, Inc. | 15 | $435 |
| Lundbeck LLC | 16 | $222 |
| Supernus Pharmaceuticals, Inc. | 12 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $160 |
| Sunovion Pharmaceuticals Inc. | 11 | $158 |
| Tris Pharma Inc | 5 | $112 |
| Neurocrine Biosciences, Inc. | 5 | $108 |
| Corium, LLC | 5 | $108 |
| Axsome Therapeutics, Inc. | 4 | $92 |
| Vanda Pharmaceuticals Inc. | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 4 | $63 |
| Vertical Pharmaceuticals, LLC | 4 | $60 |
| Shire North American Group Inc | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Ironshore Pharmaceuticals Inc. | 2 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Noven Therapeutics, LLC | 2 | $35 |
| Adlon Therapeutics L.p. | 2 | $25 |
| Almatica Pharma LLC | 1 | $19 |
| Bausch Health US, LLC | 1 | $19 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,146 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 28 | $39,763 |
| RexultiBrexpiprazole | 12 | $17,414 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $5,205 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 121 | $3,979 |
| Aripiprazole | 72 | $2,545 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 91 | $1,765 |
| Methylphenidate ErMethylphenidate Hcl | 50 | $1,550 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $1,387 |
| Bupropion XlBupropion Hcl | 82 | $1,280 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 59 | $1,207 |
| Quetiapine Fumarate | 58 | $986 |
| Sertraline Hcl | 88 | $946 |
| RivastigmineRivastigmine Tartrate | 13 | $923 |
| Gabapentin | 21 | $792 |
| Olanzapine | 37 | $776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $572 | $39,76328 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $435 | $17,41412 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $94688 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Philadelphia
- Steven ArnoldPhiladelphia$4.1M
- Michael ThasePhiladelphia$2.2M
- Daniel WeintraubPhiladelphia$647K
- Yvette ShelinePhiladelphia$442K
- Kyle KampmanPhiladelphia$355K
- Christian KohlerPhiladelphia$172K
- Freddy AliPhiladelphia$107K
- Stanley CaroffPhiladelphia$105K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.